170 related articles for article (PubMed ID: 9864183)
1. HBED: the continuing development of a potential alternative to deferoxamine for iron-chelating therapy.
Bergeron RJ; Wiegand J; Brittenham GM
Blood; 1999 Jan; 93(1):370-5. PubMed ID: 9864183
[TBL] [Abstract][Full Text] [Related]
2. HBED: A potential alternative to deferoxamine for iron-chelating therapy.
Bergeron RJ; Wiegand J; Brittenham GM
Blood; 1998 Feb; 91(4):1446-52. PubMed ID: 9454776
[TBL] [Abstract][Full Text] [Related]
3. HBED ligand: preclinical studies of a potential alternative to deferoxamine for treatment of chronic iron overload and acute iron poisoning.
Bergeron RJ; Wiegand J; Brittenham GM
Blood; 2002 Apr; 99(8):3019-26. PubMed ID: 11929795
[TBL] [Abstract][Full Text] [Related]
4. Improvement of iron removal from the reticuloendothelial system by liposome encapsulation of N,N'-bis[2-hydroxybenzyl]-ethylenediamine-N,N'-diacetic acid (HBED). Comparison with desferrioxamine.
Lau EH; Cerny EA; Wright BJ; Rahman YE
J Lab Clin Med; 1983 May; 101(5):806-16. PubMed ID: 6403640
[TBL] [Abstract][Full Text] [Related]
5. Novel double prodrugs of the iron chelator N,N'-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid (HBED): Synthesis, characterization, and investigation of activation by chemical hydrolysis and oxidation.
Thiele NA; Abboud KA; Sloan KB
Eur J Med Chem; 2016 Aug; 118():193-207. PubMed ID: 27128183
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the desferrithiocin pharmacophore as a vector for hydroxamates.
Bergeron RJ; McManis JS; Bussenius J; Brittenham GM; Wiegand J
J Med Chem; 1999 Jul; 42(15):2881-6. PubMed ID: 10425097
[TBL] [Abstract][Full Text] [Related]
7. Development and evaluation of the improved iron chelating agents EHPG, HBED and their dimethyl esters.
Hershko C; Grady RW; Link G
Haematologia (Budap); 1984; 17(1):25-33. PubMed ID: 6427069
[TBL] [Abstract][Full Text] [Related]
8. Enhanced iron removal from liver parenchymal cells in experimental iron overload: liposome encapsulation of HBED and phenobarbital administration.
Rahman YE; Cerny EA; Lau EH; Carnes BA
Blood; 1983 Jul; 62(1):209-13. PubMed ID: 6407548
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of a novel iron chelator (HBED; (N,N'-Di(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid)) in equine (Equus caballus) as a model for black rhinoceros (Diceros bicornis).
Sullivan KE; Lavin SR; Livingston S; Knutson M; Valdes EV; Warren LK
J Anim Physiol Anim Nutr (Berl); 2022 Sep; 106(5):1107-1117. PubMed ID: 35894091
[TBL] [Abstract][Full Text] [Related]
10. Results from a phase I clinical trial of HBED.
Grady RW; Salbe AD; Hilgartner MW; Giardina PJ
Adv Exp Med Biol; 1994; 356():351-9. PubMed ID: 7887241
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and tissue distribution of deferoxamine-based nanochelator in rats.
Jones G; Zeng L; Stiles WR; Park SH; Kang H; Choi HS; Kim J
Nanomedicine (Lond); 2022 Sep; 17(22):1649-1662. PubMed ID: 36547231
[TBL] [Abstract][Full Text] [Related]
12. ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture.
Hershko C; Konijn AM; Nick HP; Breuer W; Cabantchik ZI; Link G
Blood; 2001 Feb; 97(4):1115-22. PubMed ID: 11159545
[TBL] [Abstract][Full Text] [Related]
13. First human studies with a high-molecular-weight iron chelator.
Dragsten PR; Hallaway PE; Hanson GJ; Berger AE; Bernard B; Hedlund BE
J Lab Clin Med; 2000 Jan; 135(1):57-65. PubMed ID: 10638695
[TBL] [Abstract][Full Text] [Related]
14. Chelator-induced iron excretion in iron-overloaded marmosets.
Sergejew T; Forgiarini P; Schnebli HP
Br J Haematol; 2000 Sep; 110(4):985-92. PubMed ID: 11054093
[TBL] [Abstract][Full Text] [Related]
15. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture.
Link G; Konijn AM; Breuer W; Cabantchik ZI; Hershko C
J Lab Clin Med; 2001 Aug; 138(2):130-8. PubMed ID: 11477380
[TBL] [Abstract][Full Text] [Related]
16. Antimalarial effect of HBED and other phenolic and catecholic iron chelators.
Yinnon AM; Theanacho EN; Grady RW; Spira DT; Hershko C
Blood; 1989 Nov; 74(6):2166-71. PubMed ID: 2508794
[TBL] [Abstract][Full Text] [Related]
17. A comparison of the iron-clearing properties of 1,2-dimethyl-3-hydroxypyrid-4-one, 1,2-diethyl-3-hydroxypyrid-4-one, and deferoxamine.
Bergeron RJ; Streiff RR; Wiegand J; Luchetta G; Creary EA; Peter HH
Blood; 1992 Apr; 79(7):1882-90. PubMed ID: 1558978
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.
Piga A; Galanello R; Forni GL; Cappellini MD; Origa R; Zappu A; Donato G; Bordone E; Lavagetto A; Zanaboni L; Sechaud R; Hewson N; Ford JM; Opitz H; Alberti D
Haematologica; 2006 Jul; 91(7):873-80. PubMed ID: 16818273
[TBL] [Abstract][Full Text] [Related]
19. Investigation into Iron Chelating and Antioxidant Potential of Melilotus officinalis in Iron Dextran Induced Iron Overloaded Sprague Dawley Rat Model.
Sheikh NA; Desai TR; Tirgar PR
Drug Res (Stuttg); 2016 Dec; 66(12):618-627. PubMed ID: 27626608
[TBL] [Abstract][Full Text] [Related]
20. A Double Prodrug with Improved Membrane Permeability over the Parent Chelator HBED Provides Superior Cytoprotection against Hydrogen Peroxide.
Thiele NA; Sloan KB
ChemMedChem; 2016 Aug; 11(15):1596-9. PubMed ID: 27440560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
